RU-2024133379-A - A COMBINATION TREATMENT METHOD FOR PATIENTS WITH TRIPLE-NEGATIVE LOCALLY ADVANCED BREAST CANCER ASSOCIATED WITH BRCA MUTATION
RU2024133379ARU 2024133379 ARU2024133379 ARU 2024133379ARU-2024133379-A
Inventors
- Еналдиева Диана Артуровна
- Николаев Кирилл Станиславович
- Емельянов Александр Сергеевич
- Песоцкий Роман Сергеевич
- Комяхов Александр Валерьевич
- Амиров Николай
- Ульрих Дарья Глебовна
- Имамурзаева Лайла Зайнудиновна
- Осипенко Елизавета Юрьевна
- Беляев Алексей Михайлович
- Семиглазов Владимир Федорович
- Криворотько Петр Владимирович
- Имянитов Евгений Наумович
- Соколенко Анна Петровна
- Донских Роман Владимирович
- Жильцова Елена Константиновна
- Гиголаева Лариса Павловна
- Табагуа Тенгиз Тенгизович
- Мортада Виктория Владимировна
Assignees
- Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации
Dates
- Publication Date
- 20260506
- Application Date
- 20241106
Claims (1)
- A method for the combined treatment of patients with triple-negative locally advanced breast cancer associated with a BRCA mutation, characterized by the fact that 4 cycles of neoadjuvant polychemotherapy are performed with mitomycin-medac 10 mg/ m2 in combination with carboplatin AUC5 once every 28 days (MCarb regimen), followed by a transition to neoadjuvant chemotherapy with Paclitaxel 80 mg/ m2 on a weekly basis (MCarb - T regimen), a clinical assessment of the treatment is performed after the 2nd and 4th cycles of systemic therapy according to the MCarb regimen, after 2 weeks a control examination of the patient is performed in the amount of ultrasound examination of the mammary glands and lymph nodes, mammography in 2 projections and mammolymphoscintigraphy; against the background of systemic therapy with Paclitaxel, a control examination is carried out after the 6th and 12th administration in the amount of ultrasound examination of the mammary glands and lymph nodes, mammography in 2 projections and mammolymphoscintigraphy - after the 12th administration, followed by planning the surgical stage of treatment.